A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib-Reference-Cited by-同舟云学术

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

Published:2014-01 Issue:1 Volume:25 Page:236-240
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ganjoo K.N.,Villalobos V.M.,Kamaya A.,Fisher G.A.,Butrynski J.E.,Morgan J.A.,Wagner A.J.,D'Adamo D.,McMillan A.,Demetri G.D.,George S.

Funder

GlaxoSmithKline investigator-initiated trial fund

Ludwig Center at Dana-Farber/Harvard Cancer Center

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/1/236/394112/mdt484.pdf

Reference12 articles.

1. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib;Cauchi;Cancer Chemother Pharmacol,2012

2. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor;Sawaki;Cancer,2011

3. A multicenter phase II trial efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib;George;J Clin Oncol,2012

4. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Demetri;Lancet,2013

5. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial;Kang;Lancet Oncol,2013

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular pathology of gastrointestinal stromal tumors;Diagnostic Molecular Pathology;2024

2. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial;Molecular Cancer;2023-08-09

3. New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine;Veterinary and Comparative Oncology;2023-06-12

4. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours;Gastric Cancer;2023-03-13

5. SDHA Germline Mutations in SDH-Deficient GISTs: A Current Update;Genes;2023-03-04